Learn More
BACKGROUND Interleukins 12 and 23 have important roles in the pathophysiology of psoriasis. We assessed ustekinumab, a human monoclonal antibody directed against these cytokines, for the treatment of psoriasis. METHODS In this phase III, parallel, double-blind, placebo-controlled study, 766 patients with moderate-to-severe psoriasis were randomly assigned(More)
BACKGROUND Ustekinumab, a human monoclonal antibody against interleukins 12 and 23, has shown therapeutic potential for psoriasis. This study assessed the efficacy and safety of ustekinumab in psoriasis patients and assessed dosing intensification in partial responders. METHODS In this multicentre, phase III, double-blind, placebo-controlled study, 1230(More)
BACKGROUND Many patients with psoriasis develop psoriatic arthritis, a chronic inflammatory disease that afflicts peripheral synovial, axial, and entheseal structures. The fully human monoclonal antibody ustekinumab is an efficacious treatment for moderate-to-severe plaque psoriasis. We did a randomised, placebo-controlled, phase 3 trial to assess the(More)
BACKGROUND Skin-infiltrating lymphocytes expressing type 1 cytokines have been linked to the pathophysiology of psoriasis. We evaluated the safety and efficacy of a human interleukin-12/23 monoclonal antibody in treating psoriasis. METHODS In this double-blind, placebo-controlled trial, 320 patients with moderate-to-severe plaque psoriasis underwent(More)
OBJECTIVE Assess ustekinumab efficacy (week 24/week 52) and safety (week 16/week 24/week 60) in patients with active psoriatic arthritis (PsA) despite treatment with conventional and/or biological anti-tumour necrosis factor (TNF) agents. METHODS In this phase 3, multicentre, placebo-controlled trial, 312 adults with active PsA were randomised (stratified(More)
In this Study, Mg(2+) and Ba(2+) act to enhance the maximum emission of Sr2.97SiO5:0.03Eu(2+) significantly and redshift the emission band to the orange-red region in Sr(2.97-x-y)Mg(x)Ba(y)SiO5:0.03Eu(2+). Size mismatch between the host and the doped cations tunes the photoluminescence spectra shift systematically. A slight blue shift when increasing the(More)
A novel microfabricated breath sensor (MBS) based on multi-walled carbon nanotubes (MWNTs) has been presented and tested. It has a simple structure of two nickel beams incorporatingwithMWNTs. The responses of the MBS to the behavior of the breath dynamic characteristics are consistent with the exhalation pulse of the human-volunteers, e.g. the exhale flow(More)
BACKGROUND IL-23 expression is increased in psoriatic lesions and might regulate TH17 T-cell counts in patients with psoriasis. OBJECTIVES We sought to test a novel IL-23-specific therapeutic agent for the treatment of psoriasis. METHODS In this randomized, double-blind, placebo-controlled study the safety, tolerability, and clinical response of(More)
BACKGROUND Patients with psoriasis tend to be overweight, and the efficacy of fixed-dose biologics may be compromised by high body weight. OBJECTIVE We sought to determine whether the optimal dose of ustekinumab is affected by weight in patients with psoriasis. METHODS Patients were randomized in two phase III trials (PHOENIX 1 and 2) to receive 45 mg(More)